In vitro inhibition of murine B-cell tumor growth by MDP, MDP(D-D) and Vaccin is mediated by macrophages.
The effect of two muramyl dipeptides, N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) and N-acetylmuramyl-D-alanyl-D-isoglutamine (MDP(D-D)), on the in vitro growth of two murine ascitic plasmacytomas, MOPC 173 and TEPC 15, and on an ascitic lymphoma cell line, ABPL2, was studied. The ability of the muramyl dipeptides to inhibit tumor cell growth was compared with a sonicated antigenic preparation of Mycobacterium vaccae (Vaccin), known to have macrophage stimulation activity. The growth of all three ascitic cell lines was inhibited by both muramyl dipeptides and Vaccin. Macrophage-depletion of the ascitic cell populations led to an increase in cell growth of TEPC 15 and MOPC 173, and a decrease in ABPL2. A reduction or loss of the inhibitory activity of the muramyl dipeptides or Vaccin was also observed, and no inhibitory activity was found when the tumor cell lines were cultured in vitro to render them macrophage-free. The inhibitory activity of MDP or MDP(D-D) was restored when purified ascitic macrophages were added to the in vitro cultured cell lines. It was demonstrated that a minimum number of macrophages were necessary for the expression of inhibitory activity. Indomethacin, a PG-synthetase inhibitor, was found to act in a synergistic manner with MDP and MDP(D-D) in inhibiting TEPC 15, but antagonized the effect of these two agents on ABPL2. The lymphoma cell line ABPL2 appeared to be the most sensitive to inhibition by MDP(D-D), a nonpyrogenic, adjuvant-inactive stereoisomer of MDP.